PRecision biomArker-Guided MAnagement of TuberculosIs Contacts: a Discrete Choice Experiment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07024836

Acronym

PRAGMATIC-DCE

Enrollment

430

Registered

2025-06-17

Start date

2025-05-22

Completion date

2026-12-31

Last updated

2025-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis (TB)

Keywords

preference, discrete choice experiment, qualitative, latent tuberculosis infection

Brief summary

This study is part of a broader programme of work to develop and pilot a randomised-controlled trial of new tests to identify people who will benefit most from preventive treatment for tuberculosis (TB). The aim of the current study is to explore factors affecting patient decisions to start preventive treatment. The specific objectives are to understand how patients make decisions about preventive treatment initiation for TB (stage 1); and to design and conduct a discrete choice experiment survey to further evaluate preferences (stage 2).

Detailed description

We will perform up to 30 semi-structured interviews among people undergoing testing for latent TB infection, as part of routine clinical screening programmes (stage 1). Adults (aged ≥18 years) who have been or are being tested for LTBI in routine clinical services will be eligible for inclusion through purposive sampling. The findings from the qualitative study will then be used to inform the a discrete choice experiment (DCE). The DCE will be conducted to quantify the trade-off between future TB risk and preventive treatment acceptance, from patient and healthcare provided perspectives (stage 2).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults (aged ≥18 years) who have been tested for latent TB infection in routine clinical services, or are eligible for testing. Eligible people for testing include migrants from countries with high TB incidence (entered UK within 5 years), people with recent contact with a person with TB disease, and people eligible for LTBI screening prior to starting immunosuppression or through occupational health testing.

Exclusion criteria

* Unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Preventive treatment acceptance	Baseline	Discrete choice experiment data will be analysed to evaluate the primary outcome of preventive TB treatment acceptance in the survey.

Countries

United Kingdom

Contacts

Primary ContactRishi K Gupta, PhD

r.gupta@ucl.ac.uk020 3549 5979

Outcome results